ARTICLE | Company News
igeneon, Novartis cancer vaccine deal
October 2, 2002 7:00 AM UTC
igeneon (Vienna, Austria) exercised its option to acquire from Novartis (NVS; SWX:NOVN) exclusive worldwide rights to develop and market IGN301 cancer vaccine against epithelial cancers. NVS will rece...